Myriad Genetics, Inc. (MYGN) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

9/25

Growth 2 Margin 0 Expansion 4 Platform 1 Financial 2

latest quarter score

Earnings Reports

9
Myriad Genetics (MYGN) Q2 2026: Revenue Falls 11% as Payer Friction Pressures Hereditary Cancer Testing
July 31, 2026
15
Myriad Genetics (MYGN) Q1 2026: 100+ Rep Expansion Targets Cancer Share Gains Amid Launch Cycle
May 06, 2026
17
Myriad Genetics (MYGN) Q4 2025: Oncology Test Volumes Climb 14% as Cancer Pipeline Expands
February 25, 2026
14
Myriad Genetics (MYGN) Q3 2025: Oncology Volume Jumps 16% as Cancer Care Focus Drives Strategic Realignment
November 04, 2025
20
Myriad Genetics (MYGN) Q2 2025: Oncology Drives 14% HCT Volume Surge as Strategy Pivots to Cancer Care Continuum
August 06, 2025
13
Myriad Genetics (MYGN) Q1 2025: $35M Guidance Cut Spotlights GeneSight and Hereditary Cancer Drag
July 07, 2025
Myriad Genetics (MYGN) Q4 2024: 11% Revenue Growth Underpinned by Strategic AI Partnership and Product Innovation
March 04, 2025

Browse all companies